Zuo Y, et al. (2022) LATS1 is a central signal transmitter for achieving full type-I interferon activity. Sci Adv 8, eabj3887 35394840

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S62-p - CDK8 (mouse) ▲

Modsite: EGTGISMsACREIAL SwissProt Entrez-Gene Orthologous residues CDK8 (human): S62‑p, CDK8 (mouse): S62‑p, CDK8 (rat): S62‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  HEK293T (epithelial), mononuclear-blood Cellular systems studied:  cell lines, primary cells Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE LATS1 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE LATS1 (human) transfection of wild-type enzyme, co-immunoprecipitation, transfection of inactive enzyme, microscopy-colocalization, genetic knockout/knockin of upstream enzyme, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IFN-alpha increase siRNA IFN-alpha inhibit treatment-induced increase LATS1 shRNA IFN-beta increase Downstream Regulation Effect of modification (function):  phosphorylation Effect of modification (process):  cell growth, inhibited, transcription, induced Comments:  induces STAT1 phosphorylation

Y200-p - LATS1 (mouse) ▲

Modsite: SLGENVVyRSEsPNs SwissProt Entrez-Gene Orthologous residues LATS1 (human): Y200‑p, LATS1 (mouse): Y200‑p, LATS1 (rat): Y200‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  HEK293T (epithelial) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE Tyk2 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE Tyk2 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IFN-alpha increase siRNA IFN-alpha inhibit treatment-induced increase TYK2 shRNA IFN-alpha JAK1 (human) no effect upon treatment-induced increase JAK1 shRNA has no effect Downstream Regulation Effect of modification (function):  enzymatic activity, induced, phosphorylation Effect of modification (process):  cell growth, inhibited, signaling pathway regulation, transcription, induced Comments:  primes phosphorylation at S908 and regulates the Tyk2-LATS1-CDK8 pathway

Y277-p - LATS1 (mouse) ▲

Modsite: PSSQTKRysGNMEYV SwissProt Entrez-Gene Orthologous residues LATS1 (human): Y277‑p, LATS1 (mouse): Y277‑p, LATS1 (rat): Y277‑p Characterization Methods used to characterize site in vivo:  mass spectrometry, mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  HEK293T (epithelial) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme KINASE Tyk2 (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE Tyk2 (human) transfection of wild-type enzyme, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IFN-alpha increase siRNA IFN-alpha inhibit treatment-induced increase TYK2 shRNA IFN-alpha JAK1 (human) no effect upon treatment-induced increase JAK1 shRNA has no effect Downstream Regulation Effect of modification (function):  enzymatic activity, induced, phosphorylation Effect of modification (process):  cell growth, inhibited, signaling pathway regulation, transcription, induced Comments:  primes phosphorylation at S908 and regulates the Tyk2-LATS1-CDK8 pathway

S908-p - LATS1 (mouse) ▲

Modsite: HQRCLAHsLVGTPNY SwissProt Entrez-Gene Orthologous residues LATS1 (human): S909‑p, LATS1 (mouse): S908‑p, LATS1 (rat): S909‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lung cancer, non-small cell lung cancer, non-small cell lung adenocarcinoma, fibrosarcoma of soft tissue Relevant cell lines - cell types - tissues:  2fTGH (fibroblast), A549 (pulmonary), HT1080 (fibroblast), lung, MEF (fibroblast), mononuclear-blood, spleen Cellular systems studied:  cell lines, primary cells, tissue Species studied:  human, mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IFN-alpha increase IFN-beta increase IFN-gamma no change compared to control IFN-Lambda 3 no change compared to control IFN-beta IFNAR1 (human) augment treatment-induced increase IFNAR1 KO inhibits IFN-beta MST1 (human) no effect upon treatment-induced increase MST1 deficiency has no effect IFN-alpha MST2 (human) augment treatment-induced increase MST2 deficiency has no effect TNF no change compared to control IL-6 no change compared to control Downstream Regulation Effect of modification (function):  enzymatic activity, induced, intracellular localization, phosphorylation Effect of modification (process):  cell growth, inhibited, signaling pathway regulation, transcription, induced Comments:  induces YAP1 phosphorylation and regulates the Tyk2-LATS1-CDK8 pathway

S727-p - STAT1 (mouse) ▲

Modsite: tDNLLPMsPEEFDEM SwissProt Entrez-Gene Orthologous residues STAT1 (human): S727‑p, STAT1 iso2 (human): ‑, STAT1 (mouse): S727‑p, STAT1 (rat): S727‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  fibrosarcoma of soft tissue Relevant cell lines - cell types - tissues:  2fTGH (fibroblast), HEK293T (epithelial), HeLa (cervical), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  human, mouse Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CDK8 (human) pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme, phospho-antibody Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IFN-alpha increase IFN-beta increase IFN-alpha LATS1 (human) augment treatment-induced increase LATS1 shRNA inhibits IFN-beta LATS1 (human) augment treatment-induced increase LATS1 shRNA inhibits IFN-beta LATS2 (human) no effect upon treatment-induced increase LATS2 KD has no effect IFN-alpha LATS2 (human) no effect upon treatment-induced increase Go_6983 LATS1 (human) no effect upon treatment-induced increase SB202190 LATS1 (human) no effect upon treatment-induced increase MSC2530818 IFN-alpha inhibit treatment-induced increase MSC2530818 LATS1 (human) inhibit treatment-induced increase siRNA IFN-alpha inhibit treatment-induced increase CDK8 shRNA Downstream Regulation Effect of modification (process):  cell growth, inhibited, transcription, induced

S112-p - YAP1 (mouse) ▲

Modsite: PQHVRAHssPAsLQL SwissProt Entrez-Gene Orthologous residues YAP1 (human): S127‑p, YAP1 iso2 (human): S127‑p, YAP1 iso3 (human): S127‑p, YAP1 iso5 (human): S127‑p, YAP1 iso6 (human): S127‑p, YAP1 iso7 (human): S127‑p, YAP1 iso8 (human): S127‑p, YAP1 iso9 (human): S127‑p, YAP1 (mouse): S112‑p, YAP1 (rat): S112‑p, YAP1 iso3 (rat): S112‑p, YAP1 (sheep): S42‑p, YAP1 (cow): S55‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  HEK293T (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE LATS1 (human) genetic knockout/knockin of upstream enzyme, siRNA inhibition of enzyme, phospho-antibody Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes IFN-alpha increase siRNA IFN-alpha inhibit treatment-induced increase LATS1 shRNA IFN-alpha LATS2 (human) no effect upon treatment-induced increase LATS2 shRNA has no effect Downstream Regulation Effect of modification (function):  protein degradation Effect of modification (process):  cell growth, inhibited, transcription, inhibited